Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Colorado, Denver
This is a pilot study of 10 patients that have COPD-PH. Primary outcome measure is to see if this drug is safe for this patient population and the secondary measure is to see if the drug improves patient functional capacity.
Age
30–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
be between the ages of 30 and 80
have a clinical diagnosis of Gold stage 2 to 4 COPD
have a diagnosis of pulmonary hypertension established by a historic right heart catheterization
a minimum weight of 45 Kg
minimum systolic blood pressure of \>90 mmHg
be able to perform a six minute walk test
be able to maintain a oxygen saturation \>88% at rest (with or without oxygen)
be treated with background therapy for COPD for a minimum of 1 month prior to consideration of enrollment.
be competent to understand the information given in the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved Informed Consent Form and must sign the form prior to the initiation of any study procedure.
You may not be if
The presence of pulmonary venous hypertension defined by a historical right heart catheterization
Gold Stage I COPD
documented left ventricular dysfunction as measured by echocardiography
pregnant or breastfeeding
Recipient of a lung transplant
received chronic prostanoid therapy for pulmonary hypertension within 4 weeks prior to the screening appointment
A requirement of greater than 9 l/min of O2 to maintain oxygen saturations greater than 88% at rest
No other serious medical conditions
Clareo Health | Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1
